The Certara Blog

Author: Amin Rostami

Amin Rostami is Certara's Chief Scientific Officer. Dr. Rostami leads a team of scientists working on extrapolation of in vitro data on drug metabolism to predict in vivo pharmacokinetics and pharmacodynamics in virtual patient populations. He has authored/co-authored around 115 peer-reviewed full articles. Dr. Rostami has been the Scientific Secretary of PKUK (the UK discussion group on PK) since 1998, elected Scientific Secretary for the Drug Metabolism Committee of IUPHAR since 2010, and is an elected member of the EUFEPS Council. Currently he serves on the EUFEPS Committee on Industrial Research Relation, the HESI Emerging Issues Steering Committee (EISC), the ISSX Finance Committee and the Host Madsen Award Committee of FIP. He also serves on the editorial boards of Biopharmaceutics and Drug Disposition, Drug Metabolism & Pharmacokinetics, Current Drug Metabolism, Frontiers in Drug Metabolism and Transport and Frontiers in Toxicity Prediction and Xenobiotica. He has been an invited speaker at over 110 national and international meetings and he regularly leads hands-on workshops on model-based drug development. In November 2011, Amin was awarded a Japanese Society for the Study of Xenobiotics (JSSX) Fellowship for being ‘a distinguished contributor and acknowledged leader in the advancement of the study of xenobiotics’. Dr. Rostami received his PharmD from Tabriz Medical Sciences University in 1987, and his PhD from the University of Sheffield in 1996. He was a Research Assistant to Professor Geoff Tucker before progressing to Lecturer (1997), Senior Lecturer (2002), Reader (2005) and Professor (2008) at Sheffield. He became Chair of Systems Pharmacology at the Centre for Applied Pharmacokinetic Research in the School of Pharmacy and Pharmaceutical Sciences at the University of Manchester, UK in 2009.

Recent Posts

5 Certara Posters You Should Have Seen at ASCPT 2015

I attended and contributed to the recent annual meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) in New Orleans. This is a meeting that I have attended regularly in the past. It was a valuable opportunity to see some truly innovative scientific approaches to the toughest challenges in drug development. If I […]

Read More
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog